Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
103 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Atrial Fibrillation - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Atrial Fibrillation - Pipeline Review, H1 2015', provides an overview of the Atrial Fibrillation's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Atrial Fibrillation - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Atrial Fibrillation and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Atrial Fibrillation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Atrial Fibrillation pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Atrial Fibrillation - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Atrial Fibrillation pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Atrial Fibrillation Overview 9 Therapeutics Development 10 Pipeline Products for Atrial Fibrillation - Overview 10 Pipeline Products for Atrial Fibrillation - Comparative Analysis 11 Atrial Fibrillation - Therapeutics under Development by Companies 12 Atrial Fibrillation - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Atrial Fibrillation - Products under Development by Companies 17 Atrial Fibrillation - Companies Involved in Therapeutics Development 19 ARCA biopharma, Inc. 19 Armetheon, Inc. 20 AstraZeneca PLC 21 Bristol-Myers Squibb Company 22 Cardiome Pharma Corp 23 Daiichi Sankyo Company, Limited 24 Gilead Sciences, Inc. 25 Isis Pharmaceuticals, Inc. 26 Laboratoires Pierre Fabre SA 27 Nissan Chemical Industries, Ltd. 28 Nyken BV 29 Otsuka Holdings Co., Ltd. 30 Regado Biosciences, Inc. 31 Serodus ASA 32 Xention Limited 33 Atrial Fibrillation - Therapeutics Assessment 34 Assessment by Monotherapy Products 34 Assessment by Combination Products 35 Assessment by Target 36 Assessment by Mechanism of Action 38 Assessment by Route of Administration 40 Assessment by Molecule Type 42 Drug Profiles 44 (ranolazine + dronedarone) - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Aptamers for Cardiovascular Diseases - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 BMS-919373 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 bucindolol hydrochloride - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 budiodarone - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Drug For Atrial Fibrillation - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 edoxaban tosylate - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 F-373280 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 GsMTx-4 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 ISIS-CRPRx - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 NIP-151 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 NYK-1112 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 OMT-33 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 OPC-108459 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 ranolazine ER - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 SER-102 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Small Molecule to Block IKACh for Atrial Fibrillation - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Small Molecules to Activate Heat Shock Protein 70 (Hsp70) for Post-Operative Atrial Fibrillation - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Small Molecules to Block Voltage Gated Sodium Channel for Atrial Fibrillation - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 vanoxerine - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 vernakalant hydrochloride - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 XEN-D0101 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 XEN-D0103 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 XEN-R0702 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Atrial Fibrillation - Recent Pipeline Updates 78 Atrial Fibrillation - Dormant Projects 90 Atrial Fibrillation - Discontinued Products 94 Atrial Fibrillation - Product Development Milestones 95 Featured News & Press Releases 95 Dec 08, 2014: Daiichi Sankyo Launches New Formulation of LIXIANA 60 mg Tablets (edoxaban) in Japan 95 Nov 07, 2014: Cardiome Announces Positive Results from the BRINAVESS Asia-Pacific Phase 3 Clinical Trial 95 Nov 07, 2014: Cardiome Submits BRINAVESS Reimbursement Dossier to Italian Authorities to Support Market Access 96 Oct 31, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo's Once-Daily SAVAYSA� (edoxaban) for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation 96 Oct 28, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo's Once-Daily SAVAYSA for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation 97 Sep 26, 2014: Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA (edoxaban) in Japan 98 Sep 02, 2014: Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes 98 Sep 01, 2014: Xention commences first phase 2 study of XEN-D0103 in atrial fibrillation 100 Aug 25, 2014: Cardiome Enters Commercialization Agreement With Eurolab Especialidades Medicinales For BRINAVESS In Argentina 101 Aug 06, 2014: Cardiome Submits Brinavess Dossier To French Authorities To Support Market Access 101 Appendix 102 Methodology 102 Coverage 102 Secondary Research 102 Primary Research 102 Expert Panel Validation 102 Contact Us 103 Disclaimer 103
List of Tables Number of Products under Development for Atrial Fibrillation, H1 2015 10 Number of Products under Development for Atrial Fibrillation - Comparative Analysis, H1 2015 11 Number of Products under Development by Companies, H1 2015 13 Comparative Analysis by Late Stage Development, H1 2015 14 Comparative Analysis by Clinical Stage Development, H1 2015 15 Comparative Analysis by Early Stage Development, H1 2015 16 Products under Development by Companies, H1 2015 17 Products under Development by Companies, H1 2015 (Contd..1) 18 Atrial Fibrillation - Pipeline by ARCA biopharma, Inc., H1 2015 19 Atrial Fibrillation - Pipeline by Armetheon, Inc., H1 2015 20 Atrial Fibrillation - Pipeline by AstraZeneca PLC, H1 2015 21 Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Company, H1 2015 22 Atrial Fibrillation - Pipeline by Cardiome Pharma Corp, H1 2015 23 Atrial Fibrillation - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 24 Atrial Fibrillation - Pipeline by Gilead Sciences, Inc., H1 2015 25 Atrial Fibrillation - Pipeline by Isis Pharmaceuticals, Inc., H1 2015 26 Atrial Fibrillation - Pipeline by Laboratoires Pierre Fabre SA, H1 2015 27 Atrial Fibrillation - Pipeline by Nissan Chemical Industries, Ltd., H1 2015 28 Atrial Fibrillation - Pipeline by Nyken BV, H1 2015 29 Atrial Fibrillation - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 30 Atrial Fibrillation - Pipeline by Regado Biosciences, Inc., H1 2015 31 Atrial Fibrillation - Pipeline by Serodus ASA, H1 2015 32 Atrial Fibrillation - Pipeline by Xention Limited, H1 2015 33 Assessment by Monotherapy Products, H1 2015 34 Assessment by Combination Products, H1 2015 35 Number of Products by Stage and Target, H1 2015 37 Number of Products by Stage and Mechanism of Action, H1 2015 39 Number of Products by Stage and Route of Administration, H1 2015 41 Number of Products by Stage and Molecule Type, H1 2015 43 Atrial Fibrillation Therapeutics - Recent Pipeline Updates, H1 2015 78 Atrial Fibrillation - Dormant Projects, H1 2015 90 Atrial Fibrillation - Dormant Projects (Contd..1), H1 2015 91 Atrial Fibrillation - Dormant Projects (Contd..2), H1 2015 92 Atrial Fibrillation - Dormant Projects (Contd..3), H1 2015 93 Atrial Fibrillation - Discontinued Products, H1 2015 94
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
